MyCell Products
MyCell® Products provide human induced pluripotent stem (iPS) cells and terminally differentiated cells manufactured from your donor samples to meet your specific needs. MyCell® Products include iPS cell reprogramming, genetic engineering, and cell differentiation. Choose the MyCell Products your research requires. MyCell® Products Benefits: “Footprint-free” iPS Cells - Reprogramming factors are introduced using non-inte…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
MyCell® Products provide human induced pluripotent stem (iPS) cells and terminally differentiated cells manufactured from your donor samples to meet your specific needs.
MyCell® Products include iPS cell reprogramming, genetic engineering, and cell differentiation. Choose the MyCell Products your research requires.
MyCell® Products Benefits:
- “Footprint-free” iPS Cells - Reprogramming factors are introduced using non-integrating episomal vectors that are gradually lost from the iPS cells.
- Convenient, Non-invasive Tissue Source
- Feeder-free Cell Culture
- Complete Product Offering - CDI offers a complete suite of iPS cell reprogramming, genetic engineering, and cell differentiation products to meet all project needs.
Applying Transfection Technologies to Create Novel Screening Models
The availability of human induced pluripotent stem cell (iPSC)-derived cells offers new opportunities for the generation of novel, physiologically relevant cellular models for drug screening and development. Realizing the full potential of these cellular models requires molecular techniques that enable introduction of exogenous genes and/or modulation of endogenous genetic elements. In this application note read how various types of iPSCs are compatible with transfection reagents to deliver, plasmid DNA, siRNA and reporter gene constructs. This enables investigation of specific target genes for numerous applications in drug discovery research.
Applying Transfection Technologies to Create Novel Screening Models
This Application Note highlights how iCell products are compatible with a variety of commercially available transfection reagents, thus enabling the regulation of specific target genes for numerous applications in drug discovery research. Transfection reagents were evaluated for delivery of plasmid DNA, small interfering RNA (siRNA) oligonucleotides, and reporter gene constructs.
Roberto Iacone, Roche, Discusses the Use of Stem Cells in Diabetic Cardiomyopathy Research
Dr. Iacone describes the incorporation of iPSC-derived iCell® and MyCell® Cardiomyocytes into their research program in diabetic cardiomyopathy associated with Type II diabetes and how these cells may enable development of personalized medicine.
